ASSESS-Sepsis An exploratory cohort study to assess immune phenotypes in sepsis patients

ASSESS-Sepsis An exploratory cohort study to assess immune phenotypes in sepsis patients - ASSESS-sepsis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021074

Enrollment

Registered

2020-10-01

Start date

2021-03-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41.9

Interventions

Group 1: On day 1, 3 and 7 of their ICU stay 10ml of blood will be drawn from patients with sepsis to assess their immune phenotype using various methods (incl. flow cytometry, ELISA, scRNAseq). 1 yea

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suspected sepsis based on the current international sepsis-3 consensus definition; Suspected infection and a SOFA score >2

Exclusion criteria

Exclusion criteria: preexisting immunodeficiency, immunosuppressive therapy within the last 3 month, previous resuscitation, transfer from another ICU, active hepatitis or AIDS disease

Design outcomes

Primary

Measure	Time frame
Primary outcome is the identification of patient cluster based on their immune phenotype and their correlation with the 30d and 1year mortality.	—

Secondary

Measure	Time frame
Secondary outcomes are the identification of involved mechanism and signaling pathways as well as the incidence of secondary infections, length of hospitalization, readmittance rate and the development of a chronicle critical illness (CCI)	—

Countries

Germany

Contacts

Public ContactMartin Schlegel

Klinikum rechts der Isar der TU München, Klinik für Anästhesiologie und Intensivmedizin

Martin.schlegel@tum.de0049 89 4041 4291

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026